Lutroo Imaging

Lutroo Imaging is a clinical-stage molecular imaging company developing positron emission tomography (PET) radiotracers that target voltage-gated sodium channels (NaVs). According to the company, NaVs are essential for normal electrical signaling in nerves, muscles, the heart and other cells, and abnormal NaV expression or activity is associated with cancer, chronic pain, neurological disorders, cardiac disease and many other conditions. Despite this biological importance, NaV activity has not been directly accessible through conventional clinical imaging. Lutroo's stated goal is to make this biology visible in order to enable better diagnosis, patient selection, treatment decisions and drug development. The company's lead program is Radiocaine™, described as a first-in-class PET radiotracer targeting NaVs. Radiocaine is now in clinical development and is being evaluated as a molecular imaging biomarker across multiple diseases, with initial applications in oncology and pain. In oncology, the intended use is to detect and characterize NaV-expressing tumors; in pain, the tracer is being explored as a way to image the biology underlying chronic pain. The company frames its work around a large unmet need: it cites that one in five adults worldwide suffers from chronic pain, that there are roughly 21 million new cancer cases worldwide each year, that about 3 billion people worldwide have a neurological condition, and that around 90% of drugs entering clinical development fail. Lutroo Imaging presents itself as a clinical-stage company rather than a commercial-stage pharmaceutical manufacturer, meaning its near-term value lies in its imaging-agent pipeline and clinical evidence rather than marketed products. Its business model centers on proprietary PET radiotracers that could serve as biomarkers for diagnosis, patient stratification and drug development, potentially partnering with pharmaceutical companies that need better tools to select patients and measure target engagement. The company is based in the United States and maintains its primary web presence at lutrooimaging.com. Detailed public information about its founding, financing, leadership and ownership is limited in the available sources, and this dossier reflects that limited evidence base.

Lutroo Imaging is a clinical-stage molecular imaging company based in the United States. Publicly available evidence about the company is limited and centers on its scientific focus rather than a detailed corporate chronology. The company describes itself as developing first-in-class PET imaging agents targeting voltage-gated sodium channels (NaVs), with applications across cancer, pain and other diseases. Its stated premise is that NaVs play important roles in cancer, pain, neurological disease and other conditions, yet their activity has never been directly accessible through clinical imaging. Lutroo's goal is to make this biology visible, enabling better diagnosis, patient selection, treatment decisions and drug development. The company's lead asset is Radiocaine™, a first-in-class PET radiotracer targeting NaVs. Radiocaine is now in clinical development and is being evaluated as a molecular imaging biomarker across multiple diseases, with initial applications in oncology and pain. In oncology, the company aims to detect and characterize NaV-expressing tumors; in pain, it is exploring the imaging of NaV biology associated with chronic pain. Lutroo frames the opportunity around large patient populations: it cites that one in five adults worldwide suffer from chronic pain, that there are about 21 million new cancer cases worldwide each year, that roughly 3 billion people worldwide have a neurological condition, and that about 90% of drugs entering clinical development fail. Because the company is clinical-stage, its history to date is primarily a research and development narrative rather than a commercial one. No marketed products, manufacturing operations, revenue figures, financing rounds, acquisitions or leadership changes are documented in the available evidence. The company maintains its primary web presence at lutrooimaging.com and is associated with the United States. As clinical development of Radiocaine progresses, the company's history is likely to be defined by trial results, regulatory interactions and potential partnerships with pharmaceutical developers seeking better imaging biomarkers for patient selection and target engagement.

Clinical-stage molecular imaging company developing first-in-class PET imaging agents targeting voltage-gated sodium channels (NaVs), with applications across cancer, pain, and other diseases.

• Radiocaine™

  Lutroo's first-in-class PET radiotracer targeting voltage-gated sodium channels (NaVs). Now in clinical development, Radiocaine is being evaluated as a molecular imaging biomarker across multiple diseases, with initial applications in oncology and pain.

1. 1Lutroo Imaging | Seeing NaV Biology for the First Timelutrooimaging.com
2. 2Lutroo Imagingwikidata.org